| Case Name | Drug | Patent No(s). | Publicly Available Terms |
|---|---|---|---|
| Amgen v. Hetero USA Inc., 16-0928 (D. Del.) | Sensipar® (cinacalcet HCl tablets) | 9,375,405 | N/A |
| AstraZeneca AB v. MSN Labs. Private Ltd., 15-3383 (D.N.J.) | Daliresp® (roflumilast tablets) | 8,536,206 8,604,064 8,618,142 |
N/A |
| Allergan, Inc. v. Innopharma, Inc., 15-1504 (E.D. Tex.) | Restasis® (cyclosporine ophthalmic emulsion) | 8,629,111 8,633,162 8,642,556 8,648,048 8,685,930 9,248,191 |
InnoPharma will be allowed to market its generic version of Restasis in February 2024 or possibly earlier. InnoPharma may also be allowed to launch an authorized generic version of the drug with Allergan as the supplier in August 2024. |
| Janssen Pharmaceutica, N.V. v. Mylan Pharms., Inc. 15-0760 (D. Del.) | Complera® (emtricitabine, rilpivirine, and tenofovir) | 8,841,310 7,125,879 8,101,629 8,080,551 7,399,856 7,563,922 8,101,752 8,618,291 |
Mylan may enter the market with its generic equivalent at some undisclosed date under a license agreement entered into by the parties. |
Related Attorneys
Counsel
